Calidi Biotherapeutics Inc.
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade… Read more
Calidi Biotherapeutics Inc. (CLDI) - Net Assets
Latest net assets as of September 2025: $7.20 Million USD
Based on the latest financial reports, Calidi Biotherapeutics Inc. (CLDI) has net assets worth $7.20 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.03 Million) and total liabilities ($6.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.20 Million |
| % of Total Assets | 51.31% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Calidi Biotherapeutics Inc. - Net Assets Trend (2020–2024)
This chart illustrates how Calidi Biotherapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Calidi Biotherapeutics Inc. (2020–2024)
The table below shows the annual net assets of Calidi Biotherapeutics Inc. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.97 Million | +123.90% |
| 2023-12-31 | $-8.23 Million | +83.67% |
| 2022-12-31 | $-50.44 Million | -123.08% |
| 2021-12-31 | $-22.61 Million | -0.58% |
| 2020-12-31 | $-22.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Calidi Biotherapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8727800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.13% |
| Other Comprehensive Income | $-28.00K | -1.83% |
| Other Components | $123.28 Million | 8036.18% |
| Total Equity | $1.53 Million | 100.00% |
Calidi Biotherapeutics Inc. Competitors by Market Cap
The table below lists competitors of Calidi Biotherapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ICDX
PINK:ICDX
|
$1.89 Million |
|
Ocean Glass Public Company Limited
BK:OGC
|
$1.89 Million |
|
Entreparticuli
PA:ALENT
|
$1.89 Million |
|
Malaysian Genomics Resource
KLSE:0155
|
$1.89 Million |
|
M Evo Global Acquisition Corp II Warrants
NASDAQ:MEVOW
|
$1.88 Million |
|
Comanche International Public Company Limited
BK:COMAN
|
$1.88 Million |
|
Zephyr Minerals Ltd
PINK:ZPHYF
|
$1.88 Million |
|
Antelope Enterprise Holdings Ltd
NASDAQ:AEHL
|
$1.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Calidi Biotherapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -8,235,000 to 1,534,000, a change of 9,769,000.
- Net loss of 22,143,000 reduced equity.
- Dividend payments of 1,671,000 reduced retained earnings.
- New share issuances of 18,065,000 increased equity.
- Other comprehensive income increased equity by 19,000.
- Other factors increased equity by 15,499,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-22.14 Million | -1443.48% |
| Dividends Paid | $1.67 Million | -108.93% |
| Share Issuances | $18.07 Million | +1177.64% |
| Other Comprehensive Income | $19.00K | +1.24% |
| Other Changes | $15.50 Million | +1010.37% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Calidi Biotherapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.13x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-7.54 | $0.30 | x |
| 2021-12-31 | $-94.76 | $0.30 | x |
| 2022-12-31 | $-714.54 | $0.30 | x |
| 2023-12-31 | $-58.75 | $0.30 | x |
| 2024-12-31 | $2.31 | $0.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Calidi Biotherapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1443.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 9.25x
- Recent ROE (-1443.48%) is below the historical average (-288.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.69 Million |
| 2021 | 0.00% | -2434.97% | 0.13x | 0.00x | $-8.67 Million |
| 2022 | 0.00% | -56504.44% | 0.02x | 0.00x | $-20.38 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.39 Million |
| 2024 | -1443.48% | 0.00% | 0.00x | 9.25x | $-22.30 Million |
Industry Comparison
This section compares Calidi Biotherapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Calidi Biotherapeutics Inc. (CLDI) | $7.20 Million | 0.00% | 0.95x | $1.88 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |